Virtual histology evaluation of atherosclerosis regression during atorvastatin and ezetimibe administration: HEAVEN study
Jazyk angličtina Země Japonsko Médium print-electronic
Typ dokumentu časopisecké články, randomizované kontrolované studie, Research Support, N.I.H., Extramural, práce podpořená grantem
Grantová podpora
R01 HL063373
NHLBI NIH HHS - United States
PubMed
22076422
DOI
10.1253/circj.cj-11-0730
PII: JST.JSTAGE/circj/CJ-11-0730
Knihovny.cz E-zdroje
- MeSH
- anticholesteremika terapeutické užití MeSH
- aterosklerotický plát diagnostické zobrazování farmakoterapie patologie MeSH
- atorvastatin MeSH
- azetidiny terapeutické užití MeSH
- cholesterol metabolismus MeSH
- ezetimib MeSH
- intervenční ultrasonografie MeSH
- jednoduchá slepá metoda MeSH
- kombinovaná farmakoterapie MeSH
- koronární cévy diagnostické zobrazování metabolismus patologie MeSH
- kyseliny heptylové terapeutické užití MeSH
- lidé středního věku MeSH
- lidé MeSH
- lipoproteiny metabolismus MeSH
- molekuly buněčné adheze metabolismus MeSH
- nemoci koronárních tepen diagnostické zobrazování farmakoterapie patologie MeSH
- progrese nemoci MeSH
- pyrroly terapeutické užití MeSH
- senioři MeSH
- výsledek terapie MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
- Research Support, N.I.H., Extramural MeSH
- Názvy látek
- anticholesteremika MeSH
- atorvastatin MeSH
- azetidiny MeSH
- cholesterol MeSH
- ezetimib MeSH
- kyseliny heptylové MeSH
- lipoprotein cholesterol MeSH Prohlížeč
- lipoproteiny MeSH
- molekuly buněčné adheze MeSH
- pyrroly MeSH
BACKGROUND: There is no study focusing on changes in coronary atherosclerosis during dual lipid-lowering therapy with statin and ezetimibe. METHODS AND RESULTS: Eighty-nine patients with stable angina randomized in a 1:1 ratio to Group A (aggressive therapy: atorvastatin 80mg, ezetimibe 10mg) and Group S (standard therapy) were analyzed. Treatment period was 12 months. Coronary arteries were examined by intravascular ultrasound and virtual histology. We found a decrease in the percent atheroma volume (PAV) (-0.4%) in Group A compared with an increase (+1.4%) in Group S (P=0.014) and this was accompanied by an increased frequency of combined atherosclerosis regression (increased lumen volume+decreased PAV) in group A (40.5%) compared with group S (14.9%) (P=0.007). The target low-density lipoprotein cholesterol level <2mmol/L, presence of at least 4 of 5 atherosclerotic risk factors, and decreased level of vascular cellular adhesive molecule were independent predictors of plaque regression. There were no significant differences in plaque composition between the 2 groups over the study duration. However, during analysis of the 2 groups together, fibrous and fibro-fatty tissues decreased and dense calcification and necrotic core increased during follow-up. CONCLUSIONS: Dual lipid-lowering therapy starts atherosclerosis regression, but does not lead to significant changes in plaque composition. The continuous shift in plaque from fibro and fibro-fatty to necrotic with calcification was present in both groups.
Citace poskytuje Crossref.org
Effect of ezetimibe on plasma adipokines: a systematic review and meta-analysis
